Professional Documents
Culture Documents
PRESENTATION
A RARE CASE OF CO-INFECTION
THAT DID NOT END WELL
No history of prior major trauma, medical or surgical diseases. No prior hospital admissions. No
ongoing chronic medications.
Average built.
RR 26/min, regular.
She was put on Face Mask with Reservoir Bag to treat hypoxia. Her saturation increased to 95%.
To treat her hypotension, normal saline infusion was started and POCUS was performed, which revealed:
1. IVC: dilated with <18% collapsibility
2. EF: good (approximately >50%) with RV normal size and no RWMA
3. B profile: >3 in all quadrants, with pleural breaks+ in Rt side
4. B/L mild pleural effusion+ with ascites+
5. ONSD: Rt- 5.8 mm, Lt- 5.7 mm
6. DVT scan: Negative
INITIAL RESUSCITATION
Depending on the POCUS result, patient was started on Noradrenaline infusion, after placement of a central
venous line, and restricted fluid intake.
All cultures sent, ABG done and Lactate showed to be 6.7 mmol/L.
Patient remained hypotensive, tachycardic and febrile despite Noradrenaline and PCM infusion, hence
prognosticated gravely.
ABG AT ICU ADMISSION
Parameters Values
pH 7.525
pO2 54.4
pCO2 27.5
HCO3 22.2
AG 23.6
BE 1.0
AaDO2 476.5
P/F 68
Osm 272
Na 135.9
K 3.3
Cl 93.4
INVESTIGATIONS ORDERED
1. Routine investigations (CBC, LFT, RFT, RBS, Urine R/M, CXR, ECG),
2. Hepatitis profile [Hepatitis A and E IgM, PT/aPTT/INR, Serum Ammonia].
3. Ultrasound abdomen was requested.
4. Complete fever profile was sent [Covid RT-PCR, Leptospira IgM/IgG, Scrub Typhus IgM/IgG,
Typhidot, MP, MPDA, Dengue IgM/IgG].
Lumbar puncture was not performed due to possible raised ICT as evident by ONSD.
INITIALLY ADVISED TREATMENT
1. Broad spectrum antibiotic (Meropenem, Doxycyclin)
2. Hepatic encephalopathy coverage was given (Lactulose with stool target, Rifaximine)
3. Radiology ref. for USG W/A revealed normal liver/spleen size and echotexture, bilateral kidney
showed altered echogenicity and “Sweat sign” which is s/o AKI. IVC diameter was 1.36 mm and
portal vein diameter was 1.01 mm; moderate ascites and bilateral mild pleural effusion was
present.
CLINICAL PROGRESSION
24 h
AKI 10 hours
The rapidly progressive course of ‘triple infection’ in our patient suggested a possible worse
outcome than individual diseases.
So, this case opens up a possibility to initiate a prospective study in that direction, which would aid
us in treating patients, without mistakenly ruling out any of them based on one positive report.
LIMITATIONS WE FACED
1. Delayed presentation
2. Non availability of definitive tests, e.g. RT PCR for Dengue, HAV and MAT for Leptospirosis.
SCOPE OF IMPROVEMENT
1. A dedicated ‘Resuscitation Team’ in EOPD
2. Better point of care testing in EOPD
REFERENCE
1. Concurrent infection of dengue fever and hepatitis A infection: A case report; Zaki et al;
IJCCM 2011 Oct-Dec Vol 15 Issue 4.
2. Clinical predictors of dengue fever co-infected with leptospirosis among patients admitted
for dengue fever – a pilot study; Suppiah et al; J Biomed Sci. 2017; 24: 40.
3. Comparison between three rare cases of co-infection with dengue, leptospira and hepatitis
E: is early endothelial involvement the culprit in mortality?; Singh et al; Ann Med Health Sci
Res. 2014 Mar-Apr; 4(Suppl 1): S32-S34.
THANK YOU